| Literature DB >> 31897724 |
Jaime Conceição1, Oluwatomide Adeoye2, Helena Cabral-Marques2, Angel Concheiro3, Carmen Alvarez-Lorenzo3, José Manuel Sousa Lobo4.
Abstract
The development of orodispersible tablets (ODTs) for poorly soluble and poorly flowable drugs via direct compression is still a challenge. This work aimed to develop ODTs of poorly soluble drugs by combining cyclodextrins that form inclusion complexes to improve wetting and release properties, and directly compressible co-processed excipients able to promote rapid disintegration and solve the poor flowability typical of inclusion complexes. Carbamazepine (CBZ) and hydroxypropyl-β-cyclodextrin (HPβCD) were used, respectively, as a model of a poorly soluble drug with poor flowability and as a solubilizing agent. Specifically, CBZ-an antiepileptic and anticonvulsant drug-may benefit from the studied formulation approach, since some patients have swallowing difficulties or fear of choking and are non-cooperative. Prosolv® ODT G2 and F-Melt® type C were the studied five-in-one co-processed excipients. The complex was prepared by kneading. Flow properties of all materials and main properties of the tablets were characterized. The obtained results showed that ODTs containing CBZ/HPβCD complex can be prepared by direct compression through the addition of co-processed excipients. The simultaneous use of co-processing and cyclodextrin technologies rendered ODTs with an in vitro disintegration time in accordance with the European Pharmacopoeia requirement and with a fast and complete drug dissolution. In conclusion, the combination of five-in-one co-processed excipients and hydrophilic cyclodextrins may help addressing the ODT formulation of poorly soluble drugs with poor flowability, by direct compression and with desired release properties.Entities:
Keywords: F-Melt® type C; Prosolv® ODT G2; carbamazepine/hydroxypropyl-β-cyclodextrin complexes; direct compression; orally disintegrating tablets
Mesh:
Substances:
Year: 2020 PMID: 31897724 DOI: 10.1208/s12249-019-1579-5
Source DB: PubMed Journal: AAPS PharmSciTech ISSN: 1530-9932 Impact factor: 3.246